Boston Scientific Corporation $BSX Stake Reduced by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management cut its Boston Scientific stake by 45.1% in the first quarter, selling 58,923 shares and leaving it with 71,593 shares valued at about $4.49 million.
• Insiders bought shares recently, including directors Edward J. Ludwig and Cheryl Pegus; over the last 90 days, insiders acquired 9,800 shares worth $554,012.
• Boston Scientific reported strong quarterly results with EPS of $0.80 and revenue of $5.20 billion, and it also announced a $5 billion share repurchase program while analysts maintain a Moderate Buy consensus.

BI Asset Management Fondsmaeglerselskab A S cut its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 45.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,593 shares of the medical equipment provider's stock after selling 58,923 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Boston Scientific were worth $4,492,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the 4th quarter worth about $26,000. Colonial Trust Co SC lifted its position in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 231 shares during the last quarter. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific during the 4th quarter valued at about $26,000. Finally, Bangor Savings Bank boosted its stake in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 142 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. Wolfe Research lowered shares of Boston Scientific from an "outperform" rating to a "peer perform" rating in a research note on Friday, May 29th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research report on Thursday, May 28th. Bank of America decreased their price objective on Boston Scientific from $105.00 to $68.00 and set a "buy" rating for the company in a report on Monday, May 18th. Raymond James Financial restated an "outperform" rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, UBS Group cut their target price on Boston Scientific from $120.00 to $105.00 and set a "buy" rating on the stock in a research note on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.08.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of the company's stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $44.30 on Tuesday. The company's fifty day moving average is $54.37 and its two-hundred day moving average is $72.44. The company has a market cap of $65.84 billion, a P/E ratio of 18.53, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $44.05 and a 12-month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific's revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's leadership believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.